FDA
-
-
-
-
-
-
-
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
-
-
-
-
-
-
-
Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026
-
-
-
-
-
-
-
Tempus AI test outperforms standard biomarkers in predicting immunotherapy
-
-
-
-
-
-
-
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
-
-
-
-
-
-
-
Tempus Announces the Acquisition of Paige
-
-
-
-
-
-
-
Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations
-
-
-
-
-
-
-
Tempus Announces the National Launch of FDA-Approved xT CDx Test
-
329,911 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

